Related Experiment Video
Updated: Sep 16, 2025

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings
Published on: March 30, 2014
Contraceptive access and use of long-acting reversible contraceptives during the COVID-19 pandemic and beyond
Simone Crespi1, M Janelle Cambron-Mellott2, Candice Yong1
1Organon & Co., Jersey City, NJ, USA.
Background:
Changes in access to healthcare services during the COVID-19 pandemic may have impacted individuals' access to contraceptive care, including long-acting reversible contraceptives (LARCs), which require ⩾1 visit for insertion and/or removal.
Objectives:
This study aimed to describe the utilization and accessibility of contraceptive services and contraceptive methods, including LARCs, during the COVID-19 pandemic and understand individuals' preferred approaches for accessing contraceptive care and prescriptions in the future.
Design:
Cross-sectional study.
Methods:
Quantitative data were collected from US individuals assigned females at birth at risk for pregnancy and seeking contraceptive methods for pregnancy prevention (aged 18-49 years) via an online survey fielded in 2022. Measures included: contraceptive methods used pre-pandemic, during the pandemic, current, and planned for the future; the impact of the pandemic on LARC insertions/removals; site of care for contraceptive counseling, prescribing, and filling across time periods.
Results:
Analyses included 1878 respondents; mean age = 30.8 years, 86.2% cisgender female; 64.5% non-Hispanic White. The most common forms of contraception used by respondents pre-pandemic, during, and currently were the pill (31.0% (95% confidence interval (CI): 29.0%-33.2%), 31.3% (29.2%-33.4%), 28.3% (26.3%-30.4%)), male condom (10.9% (9.5%-12.3%), 12.8% (11.4%-14.4%), 13.7% (12.2%-15.3%)), intrauterine device (IUD) (8.5% (7.3%-9.8%), 9.6% (8.3%-11.0%), 10.2% (8.9%-11.6%)), implant (4.9% (4.0%-5.9%), 4.2% (3.4%-5.2%), 4.6% (3.8%-5.7%)), shot (4.8% (3.9%-5.9%), 4.3% (3.5%-5.3%), 4.0% (3.2%-5.0%)), and withdrawal (3.9% (3.1%-4.9%), 4.2% (3.4%-5.2%), 6.0% (5.0%-7.1%)), respectively. The use of these methods was consistent across time periods. Of respondents who wanted a LARC inserted (n = 446) or removed (n = 104) during the pandemic, 38.3% and 37.5%, respectively, reported their insertion/removal was impacted by the pandemic (e.g., delayed, went to a different office, used a different healthcare provider). The proportion of respondents who planned to use in-person-only services for contraceptive care and remote-only services for filling prescriptions in the future was higher than before and during the pandemic.
Conclusion:
Despite the consistency in the contraceptive methods used across time periods, the COVID-19 pandemic affected the way in which individuals received contraceptive services, particularly those seeking LARC services, which require in-person visits for insertion and removal. As we move out of the pandemic, special care should be paid to ensuring prompt access to individuals' preferred choice of contraceptive services.
Related Concept Videos
Birth Control Methods
Sexually Transmitted Infections
Issues And Trends In Healthcare Delivery System
Cost Containment
Payment for healthcare services has historically promoted adoption of costly and often unnecessary or inefficient...
Preventive Healthcare Services
Hormonal Control of the Ovarian Cycle
Before puberty, the hypothalamus releases GnRH in a low frequency, low amplitude pulsatile manner. This along with the immature hypothalamic-pituitary-gonadal axis activity, results in low estrogen levels and the absence of a fully functional ovarian cycle. At puberty, GnRH secretion increases in both frequency and...
Hormonal Regulation of the Menstrual Cycle
At puberty, GnRH begins a pulsatile release pattern, which triggers the anterior pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). The frequency and amplitude of GnRH pulses vary across the menstrual cycle, with faster pulses favoring LH release and slower pulses favoring FSH...

